Sterblichkeit bei Sepsis und septischem Schock in Deutschland. Ergebnisse eines systematischen Reviews mit Metaanalyse Translated title: Mortality in sepsis and septic shock in Germany. Results of a systematic review and meta-analysis

Abstract

Hintergrund

Verschiedene Autoren diskutieren, ob fehlende Qualitätsinitiativen und Behandlungsstandards in Deutschland im internationalen Vergleich zu höherer Sterblichkeit bei Sepsis und septischem Schock führen könnten. Dem gegenüber steht eine international anerkannte intensivmedizinische Versorgung in Deutschland, z. B. während der COVID-19-Pandemie.

Ziel der Arbeit

Ziel dieser Studie war es, die Sterblichkeit bei Sepsis und septischem Schock in Deutschland zu ermitteln und mit anderen Industrienationen zu vergleichen.

Material und Methoden

In eine systematischen Literaturrecherche wurden alle zwischen 2009 und 2020 veröffentlichten Interventions- und Beobachtungsstudien aus den Datenbanken PubMed und Cochrane Library eingeschlossen. Die 30- und 90-Tages-Sterblichkeit bei Sepsis und septischem Schock wurde in einer Metaanalyse mittels „Random-effects“-Modells gepoolt.

Ergebnisse

Insgesamt wurden 134 Studien in die Metaanalyse eingeschlossen. Die 30-Tages-Sterblichkeit bei Sepsis betrug in Deutschland 22,67 % (95 %-KI: 15,30–30,04 %), in Europa (ohne Deutschland) 23,85 % (95 %-KI: 20,49–27,21 %) und in Nordamerika 19,58 % (95 %-KI: 14,03–25,14 %). Die 30-Tages-Sterblichkeit bei septischem Schock betrug 30,48 % (95 %-KI: 29,30–31,67 %), 34,57 % (95 %-KI: 33,51–35,64 %) bzw. 33,69 % (95 %-KI: 31,51–35,86 %). Die 90-Tages-Sterblichkeit bei septischem Schock betrug 38,78 % (95 %-KI: 32,70–44,86 %), 41,90 % (95 %-KI: 38,88–44,91 %) beziehungsweise 34,41 % (95 %-KI: 25,66–43,16 %).

Diskussion

Es ergaben sich somit keine Anhaltspunkte dafür, dass die Sterblichkeit bei Sepsis/septischem Schock im internationalen Vergleich in Deutschland erhöht ist.

Zusatzmaterial online

Die Online-Version dieses Beitrags (10.1007/s00101-021-00917-8) enthält zusätzliche Informationen zu den eingeschlossenen Studien. Beitrag und Zusatzmaterial stehen Ihnen auf www.springermedizin.de zur Verfügung. Bitte geben Sie dort den Beitragstitel in die Suche ein, das Zusatzmaterial finden Sie beim Beitrag unter „Ergänzende Inhalte“.

Translated abstract

Background

The reported mortality for sepsis and septic shock varies between 15% and 59% in international comparison. For Germany, the number of studies is limited. Previous estimations of mortality in Germany are outdated or based on claims data analyses. Various authors discuss whether lacking quality initiatives and treatment standards in Germany could cause higher mortality for sepsis. This contrasts with the internationally well-recognized performance of the German intensive care infrastructure during the COVID-19 pandemic.

Objectives

The objectives of this systematic review and meta-analysis were to estimate 30-day and 90-day mortality of patients with sepsis and patients with septic shock in Germany and to compare the mortality with that of other industrialized regions (Europe, North America).

Material and methods

A systematic literature search included interventional and observational studies published between 2009 and 2020 in PubMed and the Cochrane Library that analyzed adult patients with sepsis, severe sepsis and septic shock in Europe and North America. Studies with less than 20 patients were excluded. The 30-day and 90-day mortality for sepsis and septic shock were pooled separately for studies conducted in Germany, Europe (excluding Germany) and North America in a meta-analysis using a random effects model. Mortality over time was analyzed in a linear regression model.

Results

Overall, 134 studies were included. Of these, 15 studies were identified for the estimation of mortality in Germany, covering 10,434 patients, the number of patients per study ranged from 28 to 4183 patients. The 30-day mortality for sepsis was 22.67% (95% confidence interval, CI: 15.30–30.04%) in Germany, 23.85% (95% CI: 20.49–27.21%) in Europe (excluding Germany) and 19.58% (95% CI: 14.03–25.14%) in North America. The 30-day mortality for septic shock was 30.48% (95% CI: 29.30–31.67%) in Germany, 34.57% (95% CI: 33.51–35.64%) in Europe (excluding Germany) and 33.69% (95% CI: 31.51–35.86%) in North America. The 90-day mortality for septic shock was 38.78% (95% CI: 32.70–44.86%) in Germany, 41.90% (95% CI: 38.88–44.91%) in Europe (excluding Germany) and 34.41% (95% CI: 25.66–43.16%) in North America. A comparable decreasing trend in sepsis 30-day mortality was observed in all considered regions since 2009.

Conclusion

Our analysis does not support the notion that mortality related to sepsis and septic shock in Germany is higher in international comparison. A higher mortality would not be obvious either, since intensive care, for example also during the COVID-19 pandemic, is regarded as exemplary in Germany and the structural quality, such as the number of intensive care beds per 100,000 inhabitants, is high in international comparison. Nevertheless, deficits could also exist outside intensive care medicine. A comparison of international individual studies should take greater account of the structure of healthcare systems, the severity of disease and the limitations resulting from the data sources used.